Prostate Cancer: Progress and Promise, Part III: Personalized Medicine: Do We Still Have to Treat Everyone the Same Way?

Date of Original Release:7/17/2014
Expiration Date:7/17/2016


Instructions

  • Read the following information before beginning the educational activity and click the "Continue" link at the bottom of the page.
  • View the educational activity.
  • Complete the CME post-test and evaluation.
  • After successful completion of the CME post-test and evaluation, you will receive the credit or participation certificate

*The CME post-test and evaluation must be completed by July 17, 2016 in order to receive the credit or participation certificate.

Target Audience

Physicians who wish to advance their current knowledge of prostate cancer.

Learning Objective

Describe current evidence supporting the use of clinical and molecular prognostic markers to guide treatment decisions in men with prostate cancer. 

Accreditation and Credit Designation

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The Society for Translational Oncology designates this internet enduring CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

In compliance with the ACCME Standards of Commercial Support, it is the policy of the Society for Translational Oncology to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

This activity has been reviewed by the activity moderator. Any potential conflicts of interest were resolved prior to publication. 

Faculty Disclosure(s)

Robert Jones, PhD

Institute of Cancer Sciences, University of Glasgow

Glasgow, UK

Dr. Jones discloses that he serves as consultant/advisor for Astellas, Bayer, Curevac, Den­dreon, Exelixis, Janssen, GSK, Novartis, Pfizer, Roche, Sanofi-Aventis, Steba, Takeda; receives speaker honoraria from Astellas, Janssen, GSK, Sanofi-Aventis, Takeda; and receives research funding from AstraZen­eca, Novartis, Pfizer, and Roche.

Activity Moderator Disclosure

The reviewer discloses honoraria received from Amgen, Astellas, Bayer, BNIT, Janssen, and Takeda.

Staff Planners Disclosures

No financial relationships relevant to the content of this presentation have been disclosed by the staff planners.

Commercial Support

STO is grateful for educational grants from Janssen, Endo Pharmaceuticals, and Sanofi Oncology in partial support of this enduring material CME activity.

STO acknowledges an in-kind donation from Janssen. 

Other Links

Disclaimer Privacy statement

Correspondence

Society for Translational Oncology
318 Blackwell Street, Suite 270
Durham, North Carolina 27701
Phone: (919) 433-0489
Fax: (919) 680-4411
Email: CMEAdmin@sto-online.org